Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04577963
What this trial is testing

Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Triple Negative Breast CancerEndometrial CancerSolid Tumor, Unspecified, Adult+1 more
Hutchmed 52
Not applicableStudy completedNCT06344793
What this trial is testing

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 608
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Not applicableStudy completedNCT07008963
What this trial is testing

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 48
Testing effectiveness (Phase 2)Study completedNCT02894398
What this trial is testing

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Who this might be right for
Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
iOMEDICO AG 388
Not applicableStudy completedNCT03956654
What this trial is testing

A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer

Who this might be right for
Breast Cancer
Universitaire Ziekenhuizen KU Leuven 78
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03366844
What this trial is testing

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Who this might be right for
Breast Cancer
Stephen Shiao 66
Large-scale testing (Phase 3)Study completedNCT02767661
What this trial is testing

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 263
Not applicableLooking for participantsNCT06388122
What this trial is testing

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Who this might be right for
HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more
Mayo Clinic 100
Testing effectiveness (Phase 2)Study completedNCT02983045
What this trial is testing

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Who this might be right for
MelanomaRenal Cell CarcinomaNon Small Cell Lung Cancer+4 more
Nektar Therapeutics 557
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Not applicableStudy completedNCT05022342
What this trial is testing

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 595
Testing effectiveness (Phase 2)Looking for participantsNCT05867251
What this trial is testing

Study of AVZO-021 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more
Avenzo Therapeutics, Inc. 430
Testing effectiveness (Phase 2)Study completedNCT07162051
What this trial is testing

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Xijing Hospital 28
Not applicableLooking for participantsNCT06797531
What this trial is testing

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

Who this might be right for
HR+/HER2- Early Breast Cancer
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)Looking for participantsNCT06860529
What this trial is testing

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Breast Cancer
Henan Cancer Hospital 357
Testing effectiveness (Phase 2)Looking for participantsNCT05949541
What this trial is testing

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast Cancer
Fudan University 265
Next Page